Session » Health Services Research Poster II – ACR/ARHP

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1179

Achieving Important Improvement in WOMAC Pain and Function By Three Months Post-Surgery Influences Satisfaction 1 Year Following Total Knee Replacement (TKR)

9:00AM-11:00AM: Abstract Number: 1188

Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic

9:00AM-11:00AM: Abstract Number: 1185

Cause and Rate of Hospitalization of Lupus Patients

9:00AM-11:00AM: Abstract Number: 1174

Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1186

Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1176

Experiences of Urban First Nations and Métis Patients Accessing and Navigating the Health System for Inflammatory Arthritis Care

9:00AM-11:00AM: Abstract Number: 1177

How Are Patients with Chronic Musculoskeletal Pain Conditions Being Managed Initially in the U.S.?

9:00AM-11:00AM: Abstract Number: 1181

Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines

9:00AM-11:00AM: Abstract Number: 1187

Impact of a Nurse-Led Program of Patient Self-Assessment and Self-Management Axial Spondyloarthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial

9:00AM-11:00AM: Abstract Number: 1173

Measuring the Advanced Clinician Practitioner in Arthritis Care (ACPAC) Program Trained Extended Role Practitioner (ERP) Workforce in Canada: A Profile of Practice Settings, Roles and Participation in Models of Arthritis Care in Canada

9:00AM-11:00AM: Abstract Number: 1178

Patients’ and Healthcare Professionals’ Resource Preferences for a Knowledge Translation Toolkit for Hip and Knee Replacement Rehabilitation

9:00AM-11:00AM: Abstract Number: 1189

Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective

9:00AM-11:00AM: Abstract Number: 1182

The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1183

The Distribution of Insurance in a Population-Based Cohort of SLE: Georgians Organized Against Lupus Cohort, 2012-2016

9:00AM-11:00AM: Abstract Number: 1180

The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Commercially-Insured Population in the United States Stratified By Disease Severity

9:00AM-11:00AM: Abstract Number: 1192

The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares

9:00AM-11:00AM: Abstract Number: 1191

The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care

9:00AM-11:00AM: Abstract Number: 1190

Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].